Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553878 | 0.80 | CXCR4 (0.53) | CXCR4SMN1; SMN2CYP2A13ALOX15HRH3 | |
| SCHEMBL31372331 | 0.77 | CXCR4 (0.77) | CXCR4SMN1; SMN2CYP2A13ALOX15HRH3 | |
| SCHEMBL465778 | 0.77 | CXCR4 (0.77) | CXCR4SMN1; SMN2CYP2A13ALOX15HRH3 | |
| SCHEMBL4547902 | 0.76 | CXCR4 (0.49) | CXCR4SMN1; SMN2CYP2A13ALOX15HRH3 | |
| SCHEMBL27969910 | 0.75 | CXCR4 (0.51) | CXCR4SMN1; SMN2ALOX15HRH3CYP2C9 | |
| SCHEMBL14905955 | 0.75 | CXCR4 (0.47) | CXCR4SMN1; SMN2ALOX15HRH3CYP2C9 | |
| SCHEMBL19725176 | 0.75 | CXCR4 (0.44) | CXCR4SMN1; SMN2CYP2A13ALOX15HRH3 | |
| SCHEMBL31002170 | 0.75 | CXCR4 (0.50) | CXCR4SMN1; SMN2CYP2A13ALOX15HRH3 | |
| SCHEMBL29520057 | 0.73 | SMN1; SMN2 (0.54) | CXCR4SMN1; SMN2ALOX15HRH3CYP2C9 | |
| SCHEMBL21852879 | 0.72 | CXCR4 (0.51) | CXCR4SMN1; SMN2ALOX15HRH3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | CXCR4 2654/4885SMN1; SMN2 4614/4885CYP2A13 834/4885 |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | STS, PEPD, PGLS | CXCR4 2781/4885SMN1; SMN2 4323/4885CYP2A13 844/4885 |
| US-20130252938-A1 | Antibacterial Compounds | STS, PGLS, PEPD | CXCR4 2654/4885SMN1; SMN2 4614/4885CYP2A13 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.